Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Use of Newer and Repurposed Antibiotics Against Gram-negative Bacteria in Neonates

Version 1 : Received: 30 April 2023 / Approved: 8 May 2023 / Online: 8 May 2023 (04:59:51 CEST)

A peer-reviewed article of this Preprint also exists.

Kontou, A.; Kourti, M.; Iosifidis, E.; Sarafidis, K.; Roilides, E. Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates. Antibiotics 2023, 12, 1072. Kontou, A.; Kourti, M.; Iosifidis, E.; Sarafidis, K.; Roilides, E. Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates. Antibiotics 2023, 12, 1072.

Abstract

Antimicrobial resistance has become a significant public health problem globally with multidrug resistant Gram negative (MDR-GN) bacteria being the main representatives. The emergence of these pathogens in neonatal settings threatens the well-being of vulnerable neonatal population given the dearth of safe and effective therapeutic options. Evidence from studies mainly in adults is now available for several novel antimicrobial compounds, such as new β-lactam/β-lactamase inhibitors (e.g. ceftazidime-avibactam, meropenem-vaborbactam, imipenem/cilastatin-relebactam), although old antibiotics such as colistin, tigecyclin and fosfomycin are also encombassed in the fight against MDR-GN infections that remain challenging. Data in the neonatal population are scarse, with few clinical trials enrolling neonates for the evaluation of efficacy, safety and dosing of new antibiotics, while the majority of old antibiotics are used off-label. In this article we review data about some novel and old antibiotics that are active against MDR-GN bacteria causing sepsis and are of interest to be used in the neonatal population.

Keywords

neonates; ceftazidime/avibactam; ceftolozane/tazobactam; imipenem/cilastatin-relebactam; meropenem/vaborbactam; colistin; tigecycline; fosfomycin

Subject

Medicine and Pharmacology, Pediatrics, Perinatology and Child Health

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.